Form 4: Assertio Holdings Executive Granted Stock Options and Restricted Stock Units

Paul Schwichtenberg, SVP, Chief Transformation Officer of Assertio Holdings, received stock options and restricted stock units as part of compensation.

Summary

• Paul Schwichtenberg, SVP, Chief Transformation Officer of Assertio Holdings, was granted 125,000 restricted stock units and 188,875 stock options on February 18, 2025.
• The restricted stock units represent a contingent right to receive one share of Assertio Holdings' common stock each.
• One-third of the restricted stock units and stock options are scheduled to vest on each of the first three anniversaries of the grant date, assuming continued employment.
• The stock options have an exercise price of $0.81 and expire on February 18, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity suggests confidence in the company's future, but it's a standard compensation practice.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• Vesting requirements incentivize continued employment and performance.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Assertio Holdings' stock.
• Executive departure before full vesting would result in forfeiture of unvested units and options.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of future value creation.

Industry Context

Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The size and vesting schedule of the grants are typical for similar roles in comparable companies.

Comparison to Industry Standards

• Equity compensation packages for SVPs at pharmaceutical companies typically include a mix of stock options and restricted stock units.
• The vesting schedules are generally consistent with industry norms, with vesting occurring over a three-to-four year period.
• The specific value of the grants would need to be compared to similar companies based on market capitalization and executive responsibilities.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with their own.
• Employees may be motivated by the potential for future equity grants.

Key Dates

Keywords

stock options, restricted stock units, Form 4, executive compensation, ASRT, Assertio Holdings, Paul Schwichtenberg